It is my impression that TGD is very thorough and constitutionally incapable of anything short of a deep dive into the data that he and the rest of our management so carefully develops. Clearly, that is a critical part of how he has brought A2-73 along to this critical inflection point.
Like it or not, I think a deep dive, taking everything into account possible is coming. I hope the market will appreciate his efforts.
Hopefully, this will include some clinically beneficial observations about our data, and some prescient new knowledge that supports ongoing development, and ultimate FDA approval, of A2-73 for Rett syndrome.
Market Data 
Markets 
